Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | EEF2K | O00418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26841980 | 0.91 | NR1H2 (0.33) | MTHFD2P2RX7KCNK3 | |
| SCHEMBL24470053 | 0.90 | MTHFD2 (0.32) | MAPK14MTHFD2P2RX7KCNH2KCNK3 | |
| SCHEMBL24483823 | 0.90 | MTHFD2 (0.32) | MAPK14MTHFD2P2RX7KCNH2KCNK3 | |
| SCHEMBL24469881 | 0.89 | MTHFD2 (0.33) | MAPK14MTHFD2P2RX7KCNH2KCNK3 | |
| SCHEMBL24173421 | 0.89 | ALDH1A1 (0.36) | MTHFD2P2RX7KCNK3 | |
| SCHEMBL26842658 | 0.88 | MAPT (0.35) | MTHFD2P2RX7 | |
| SCHEMBL26841938 | 0.88 | DGAT1 (0.33) | MAPK14MTHFD2P2RX7KCNH2KCNK3 | |
| SCHEMBL26842714 | 0.88 | PDE2A (0.34) | MTHFD2P2RX7KCNH2PDE2AEEF2K | |
| SCHEMBL22845526 | 0.87 | MTHFD2 (0.33) | MTHFD2P2RX7KCNH2KCNK3PDE2A | |
| SCHEMBL24483796 | 0.87 | MTHFD2 (0.36) | MTHFD2P2RX7KCNK3PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPK14 1682/4885MTHFD2 2383/4885P2RX7 2406/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPK14 1682/4885MTHFD2 2383/4885P2RX7 2406/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPK14 1682/4885MTHFD2 2383/4885P2RX7 2406/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPK14 1682/4885MTHFD2 2383/4885P2RX7 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.